GSK aims at NASH target with $1bn-plus Arrowhead allianceGlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a Share XGSK aims at NASH target with $1bn-plus Arrowhead alliancehttps://pharmaphorum.com/news/gsk-aims-at-nash-target-with-1bn-plus-arrowhead-alliance/
Janssen and Arrowhead strike $3.7bn RNAi dealJanssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B Share XJanssen and Arrowhead strike $3.7bn RNAi dealhttps://pharmaphorum.com/news/janssen-and-arrowhead-strike-3-7bn-rnai-deal/
